Comment on ESH position paper: Renal denervation-an interventional therapy of resistant hypertension

Journal of Hypertension

Volumn 30, Issue 12, 2012, Pages 2441-2442

  Sánchez Chaparro, Miguel Angel ^a,b   Valdivielso, Pedro ^a,b   González Sántos, Pedro ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; DIURETIC AGENT; IMIDAZOLINE; MOXONIDINE; RILMENIDINE;

ADRENERGIC SYSTEM; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; DRUG TOLERABILITY; HUMAN; INSULIN SENSITIVITY; KIDNEY DENERVATION; LETTER; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; RESISTANT HYPERTENSION;

EID: 84870207933     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283599bdb     Document Type: Letter

References (7)

1. Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, et al. ESH position paper: renal denervation-an interventional therapy of resistant hypertension. J Hypertens 2012; 30:837-841.
2. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51:1403-1419.
3. Mann SJ, Parikh NS. A simplified mechanistic algorithm for treating resistant hypertension: efficacy in a retrospective study. J Clin Hypertens (Greenwich) 2012; 14:191-197.
4. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M, Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376:1903-1909.
5. Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J 2012; 33:1058-1066.
6. Pöyhönen-Alho MK, Manhem K, Katzman P, Kibarskis A, Antikainen RL, Erkkola RU, et al. Central sympatholytic therapy has anti-inflammatory properties in hypertensive postmenopausal women. J Hypertens 2008; 26:2445-2449.
7. Hausberg M, Tokmak F, Pavenstädt H, Krämer BK, Rump LC. Effects of moxonidine on sympathetic nerve activity in patients with end-stage renal disease. J Hypertens 2010; 28:1920-1927.